Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great day for the company, congrats to all. The merger takes a lot of risk out of the stock and our current price becomes a level of support. The days of worrying about a total collapse in price is behind us now. We turn from speculators to investors now. In a few months, we can objectively look at the progress of this company and start making better informed decisions with the information and financial disclosures that will be available to us.
Regarding future financing, the listed company has additional options, less expensive fortunately, available now. As long as SR can avoid any 'Deerfield' type toxic financing, or any of former GP colleagues for that matter, our chance of success at this stage looks quite promising. Congrats and future best of luck to investors.
KITE helping all CRT, gene efiting stocks and cykotine switches (BLCM). Many articles suggesting this is the first acquisition of many in this group space area. Hopefully this continues to lift this stock until it is finally our turn. PFE is my wild guess as a suitor or partner. Have no idea what is taking Merck so long to advance their studies.
Approx 225k dumped on the last 5 minute candle per Ameritrade.
Disappointed we are not moving higher, but all is good. Sitting above the 50 dma, building a nice base in the 93 - 95 price channel with one recent break out attempt above and one below that range. RSI is around 50 which is further supported by a cash outflow since earnings. Stock is higher than the May secondary.
Like our chances of being considerably higher prior to our next earnings report. Such a strong second quarter report; looking for similarly strong operating results for the third.
I agree, I am as excited as the next guy, just want this merger behind us. I think it will happen this time.
Exactly on point, everything else is inconsequential without a completed merger with terms favorable to the current OMVS shareholders. There can come an upcoming inflection point where RAD decides with all its recent apparent successes, it has other options. LOI be damned.
Adding as well, strong earnings report and very promising upcoming 3rd qtr. Tremendously over done price reaction to yesterdays solid numbers report.
Agree, and mid to long term, this stock looks to be extremely well positioned. Even with a major market correction, I do not think we get hurt too bad. Very solid stock growing nicely into its already generously priced valuation.
Agree that this is a good time to ladder in. $95 good support below and future share price potential continues to look very promising. Pullback from recent euphoric high is a positive. Just need to hold on to any gain today and we will be just fine.
Take Two earnings beat on strong gaming sales sure bodes well for NVDA. AAOI pre-announced their earnings due to strong data center business; another big plus for NVDA. Liking our chances on 8/10 report.
Examples of three Reverse Mergers taking place in recent years. Though all three have some variations, access to capital on the public traded exchanges was a major motivation; streamlining the lengthy, complex and costly application process for listing was another. All brief articles. Provides a bit more color on what will be happening in our case.
2016 - Microbot Medical merging into Stemcells Inc on the Nasdaq:
First two articles detail merger plans including the initial stock transactions. Last article indicates the appreciation that was achieved after the event was closed (600%).
https://globenewswire.com/news-release/2016/11/28/893204/0/en/Microbot-Medical-Closes-Merger-Transaction-Initiates-Trading-on-NASDAQ-as-MBOT.html
https://exithub.com/israeli-med-tech-robotics-startup-microbot-to-acquire-95-of-stemcells-stem-in-reverse-merger/
http://www.massdevice.com/stemcells-soars-on-reverse-merger-with-israels-microbot-medical/
2014 - Ekso Bionics Goes Public, Raises $20.6M
Two articles highlighting the alternative financial capitalization avenues available to publically traded companies. In the first article, the reverse merger was completed and a private placement of $20M was also closed at the time of the merger providing immediate operating capital.
https://www.roboticsbusinessreview.com/health-medical/ekso_bionics_goes_public_raises_20-6m/
https://hax.co/2017/02/03/hax-investors-panel/
2017 - Synlogic to go public through reverse merger with Mirna Therapeutics
Pretty straight forward article, becoming fairly common alternative financing option.
https://www.bostonglobe.com/business/2017/05/16/cambridge-startup-synlogic-public-through-reverse-merger/vYOcSQh7of5XqkKYP7N4YK/story.html
SHOP, your assignment today is to close above the 50 dma currently set at $90.97.
Earnings per Yahoo listed for August 1st before the market open; estimate $-0.07. Last 3 week correction was healthy and needed for this stock; gives it a decent base to work off of. Would like it to trade and close above the 50 dma this week currently listed at $89.24. Some resistance at $90.50 area.
Fundamentally, SHOP is showing strength. The 2015 agreement with Amazon allowing SHOP customers to seamlessly integrate both AMZN and SHOP platforms seems to be contributing; SHOP's 1st qtr year-over-year revenue up 75%, with its Merchant Services Revenue increasing 92% year-over-year during the previous quarter. The recent May equity raise went very well, the underwriters even exercised their option (the "Over-Allotment Option") in full to purchase an additional 825,000 Class A subordinate voting shares. The $575M raised should be enough working capital for the immediate future to broaden the company's market share and enhance their data infrastructure and operations as well. And remember, the company in May raised their top line to $630M for the current year.
Into earnings, stock could very well continue to show strength provided the market remains intact. Plan to continue buying more shares through put selling. Strong stock with good long term prospects.
Don't own at present but have been watching. I think the bottom is largely in, but still forming. $25 looks likely considering higher volume on down days than up days, current trend/price channel looks steadfast lower, biotech sector continues to be rejected; IBB hopefully can catch support at its 200 DMA, not much of an ASCO bump expected, possibly (?) still flushing out buyout rumors, money flow terrible, no real catalyst to run on at the moment.
Hope I am wrong, but I think we still go lower. If $25 holds, the worst is over. If it fails, $21 can enter into the discussion. Seems like all large and mid size biotechs are taking turns getting pounded. Have plenty of first hand experience at that, my portfolio (40% biotechs) has been getting whacked. Hope I am wrong and the biotechs get back on track, just don't see that happening yet. Could be a long upcoming biotech summer.
Congrats, great trade. Been selling puts on this run from 105 myself. Trading out every week to lock in gains and rolling higher. Its been fun. Great trade for you. If NVDA continues to make AI inroads and the Data Center revenues continue to make all this possible, this could be 2016-like all over again. Have to believe Mr Market will have a few surprises for us along the way however.
Yes, underwhelmed. CVI has the reputation of aggressively working their stakes in various invested companies; apparently DNDN and CRMD have been in their stable in the past. Disappointed this is the best we could do for the ridiculous discount we offered. Things just don't feel right. Empty/over promises by Kirk and Cooper. Plan to be out if nothing material happens before the 90 day CVI lockout expiration. This thing will be optioned pinned to death.
Down 37 cents or 5% on no news today so the MM can play his little games and have all those 7 call options expire worthless. Blatant manipulation. Closed at $6.99 . . . . what a coincidence with those 2700+ 7 strike options open.
What a week, nice to be on the right side of this one. The future looks incredibly bright as well, data center revenues are expanding, gaming still kicking butt, and AI is building our future. Solid support now at $120 with a less dependable support of $125 where the stock was churning intraday.
Valuations are rich, but the current growth trend can easily sustain the current and higher share prices:
PE 50.95
Forward PE 38.11
PEG 4.36
P/Sales 11.05
P/B 12.35
LT Debt/Equity 0.35
Inst Owned 76.1%
Gross margin 58.8%
Profit margin 24.1%
Source Finviz; sb updated for 5/9/17 earnings.
Very good Q1 2017 report no matter what metric you choose to evaluate it. Inventories increased a bit (nitpicky) but cash, debt and most importantly revenue/net income all improved. Was hoping for a pull back in price after last Friday's big day for a purchase. Not happening. Sold a few May 60 putts last week.
Some CEO and CFO statements:
Revenue grew 91% over Q1 of last year to reach a record $96.2 million. Demand for our market-leading datacenter products continues to drive our exciting result this quarter. Datacenter revenue more than doubled over last year and represents our eighth consecutive quarter of record revenue.
We achieved another record non-GAAP gross margin of 43.2%, driven by continued improvement in our manufacturing process and favorable product mix.
Total revenue for the first quarter grew 91% year-over-year to reach another record $96.2 million. This was primarily driven by continued demand for our market-leading datacenter products. Datacenter revenue in the first quarter grew 104% year-over-year to reach $79.6 million or 82.7% of our Q1 revenue
AOI mainly focuses on long-reach and long-reach light transceivers, those having transmission distances of 150 meters to 2 kilometers. And there are 2 types of technologies used for long-reach transmission, parallel single mode, PSM; and CWDM. Hyperscale datacenter operators will generally use a combination of PSM and CWDM transceivers within the datacenter. And when evaluating which of these 2 technologies to deploy, they consider the cost of the transceiver as well as the cost of the fiber cable. PSM uses 8 fibers total, 4 for transmit and 4 for receive, which makes this type of fiber cable significantly more expensive compared to the 2-fiber cable used in CWDM solutions
CWDM products generally have higher gross margins than PSM due to our advanced design and manufacturing capabilities for these products
During the quarter, we had design wins with 3 new datacenter customers.
Based on current orders and forecasts from our customers, we believe that 2017 datacenter revenue should grow by more than 85% compared with 2016 and would include contributions from 3 hyperscale datacenter customers, each of whom will represent more than 10% of our annual revenue.
For the quarter, 83% of our revenue was from datacenter products, 14% from CATV products,
We expect Q2 revenue to be between $106 million and $112 million, representing 92% to 103% year-over-year growth. We expect Q2 non-GAAP gross margin to be in the range of 41% to 42.5%. Non-GAAP net income is expected to be in the range of $22.2 million to $24.3 million and non-GAAP EPS between $1.09 per share and $1.19 per share using a weighted average fully diluted share count of approximately 20.4 million shares.
Analyst Question:
Paul Jonas Silverstein, Cowen and Company, LLC, Research Division--
All right. And then, along the same lines, the 3 big Web 2.0 folks, Amazon, Facebook and Microsoft, 2 of them were 10% customers this quarter. I recognize you don't want to go too far into detail on any one of them. But if I can ask you generically in terms of one of them being less than 10%, is that just the vagaries of rollouts? Any insight you can share in terms of what's going on with that
Stefan J. Murry, Applied Optoelectronics, Inc. - CFO and Chief Strategy Officer
Sure. It's very much the same as we said last quarter, that there are some rollout vagaries, as you put it, that are occurring there. We believe very strongly that we have not lost market share with this customer. That it's just overall kind of a slow time for them in their deployments as they get ready to gear up 100 gig. And we expect them to grow in the future. And again, I don't think we've lost any share.
NVDA also reported strong data center revenues; we are in the right sector this year. How long will it last? My biggest concern is that 3 customers account for 75% of all data center revenues.
Nvidia data center revenues were very strong last qtr, a continuing trend. AAPL announced this morning a $1B data center upgrade/expansion. AAOI sells data transmission lasers and has been on a tear last three months. Going to pick some up and hold my NVDA as well. Need NVDA to solidly break above $121. Fantastic earnings report once again, this could be a fabulous long term hold.
So RAD is going to merge into the previously worthless OMVS shell and suddenly bestow all the profits and riches of their successful privately held business to the bag-holders of 17m outstanding shares of OMVS. Exactly what is OMVS bringing to the table other than a well preserved shell of a failed company? Wow, that would be grand slam home run for OMVS but that would piss me off if I was one of the original RAD investors. This makes no sense as presently being interretted. There is nothing publicly or officially shared as of yet. Part of the upcoming merger agreement could easily be a new class of stock that would be issued for prevoius RAD investors entitling them to all future RAD related earnings, and leave we bagholders out. Or possibly, so many new shares of outstanding stock would be approved and issued that our share of earnings would then be diluted back to the one penny range from where they emerged. We are actually investing in RAD through OMVS shares, hopefully we are rewarded.
With that said, I too own a few shares of OMVS. I think the share price continues to drift higher until the agreement is out, but some of the estimates here seem quite high. We have to all reevaluate once we see a written agreement. This is still a dice game, nothing more, but feeling lucky.
Withstood a tough biotech day. BBI down 1%.
I'm enjoying thinking about the possibilities just like everyone, but Im still having trouble connecting the dots.
1) what is OMVS real contribution in this matter; other than a shell with no revenue stream? There are probably 100 other "OMVS" type companies that could also be available. Why us?
2) RAD already has engineered the enhancements and has contracted with the original robot manufacturer. They already have access to a customer base. They have the enhanced product. Why do they need another third party? Do we have access to capital they don't have? Did we propose this merger idea to them first? What is RAD expecting of us?
3) NVDA is a supplier to RAD. Just because they are using their chips doesn't mean we have a guarantee of success; incremental sales. The units still have to selll on their own merit. If the chip is such an advancement, then maybe big incremental sales are possible. There are already robotic devices for security widely in use; is the RAD robot product innovative enough to dominate the market?
I'm long OMVS but holding back on my full desired amount. Just trying to get my hands around this. Sounds like there could be plenty of potential. Would love owning a mega stock.
Agree, $81 looks like a new support level bolstered with some nice volume as well. Even with a minor market correction, good support at 77.5 as well.
Per a May 5th review for what its worth:
https://stockinvest.us/technical-analysis/SHOP
Shopify Inc has broken the wide and strong rising the short-term trend up and an even stronger rising rate is indicated. For any reaction back there will now be support on the roof on the current trend broken at USD 84.16, a level that may pose a second chance to hit a runner. According to fan-theory USD 92.87 will be the next possible trend-top level and thereby pose a resistance level which may not be broken at the first attempt.
Promising pre-market with light volume, just hoping $80 is our new support. Great quarter. Looking for our nice upward trend to continue. Solid potential in this stock; like the subscription growth and emphasis to broaden US market awareness.
Need a convincing close above $105 today, would like to see a better technical position before Tuesday earnings. With AMD's slide after earnings and NVDA's own experience from their last ER (which was very good IMO), would like to see $105 as support, not resistance, at a minimum. I am confident in the company, not as confident with the "planned" market gyrations (regardless of the strong report anticipated) that will certainly follow the release.
Feel that the Risk Reward on this one is setting up nicely, good support at $70. Keep selling $70 puts with the hope of actually having the stock put to me. Upcoming earnings will be very telling; like to see a significant number of new vendors on board.
Very encouraging, solid gains for the last two sessions with a very red market tape. Impressive. With good volume as welll.
Down in pre-market again. Hope this hits support at $95 just to get it over with, so we can resume our run into earnings. Promising future, a good stock to own.
Good support around $100, want it to hold. Feels like this time, it may take a few weeks to right itself since we have gapped down below the 50 dma and the inhouse development of gpu's by AAPL reinforces their intent to enter into autonomous vehicles. Not concerned, stock should probably base a bit anyway after such an impressive year. Picked up some $105 calls.
Apologies, wrong board for drug update; got distracted. But Bakers are in with additional shares.
https://www.sec.gov/Archives/edgar/data/1358403/000114420417017097/0001144204-17-017097-index.htm
Bakers in for another 166k shares per filings yesterday. Decent base action at the moment and recent fav results from Brilacidin
http://www.nasdaq.com/press-release/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-20170327-00742
Sold 106 NVDA Mar 31 106 Puts for $1.40 this morning.
I focus on stocks that I know and would not mind owning in the event I was "put" the stock; and supported by an acceptable technical chart. Pretty basic approach. Do pretty decent selling short term puts; have an absolutely terrible record buying calls. Here to learn.
Wonder what the differentiation or advancement is in CVR's technology?? Per the description summary above: "The CSS provides a synergistic tool which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA)."
Will this be a more effective diagnostic tool?? Less expensive?? There are already screening tests publicly available that do Heart, vascular and more.
Life Line Screening
CVR sounds interesting, just hard to get a handle on it at the moment. Regardless, I am going to start a small position on Monday and continue to review.